PFKM and glioblastoma: Clotrimazole (150mg/kg, 3-weekly) led to a small but significant improvement in mouse survival (+7 days; p = 0.0272, Fig 4C), indicating that glycolysis inhibition via chemical interference is effective in the treatment of patient derived GBMs and that PFK1 is a promising target for GBM therapy.